theravance.com (TBPH): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Theravance Biopharma (TBPH)

Theravance Biopharma management focuses on developing safe organ-selective agents for the therapy of respiratory and gastrointestinal tracts. The company relies on stable royalties from Yupelri, possessing significant pricing power. The developer's strong authority is confirmed by the PEG growth potential ratio, where the value is maintained at 0.00, allowing for a pragmatic assessment of the company's market value.

TBPH - Theravance Biopharma Inc PEG Multiple over the range 07/04/2022 - 10/10/2026

Metric breakdowns and analytics for Theravance Biopharma, Inc. (TBPH)

- share price and consensus valuation forecast:
Summary company analytics:Theravance
Mass-produced product of theravance.com

Amidst price wars in the respiratory therapy segment and pressure from generics, the resilience of Theravance Biopharma (TBPH) depends on its ability to convert patient loyalty into profit growth. The PEG ratio trend compares the current P/E with earnings growth rates: values below one signal that the asset is undervalued relative to its expansion. Analysis of this chart reveals the company's fundamental potential, separating market noise from real operational efficiency.

Competing companies

HLN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Kenvue Inc KVUE|Verona Pharma (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|Ligand - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company - Growth-Adjusted Payback Ratio|ALVO (Alvotech S.A.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate liquidia.com LQDA|Price/Earnings to Growth Ratio Galapagos (GLPG)|ANIP (ANI Pharmaceuticals, Inc.) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Afrezza MNKD|PEG Multiple Amphastar Corp AMPH|Pacira Corp - PEG Multiple|Growth-Adjusted Payback Ratio SPRY (ars-pharma.com)|AQST (aquestive.com) - Price/Earnings to Growth Multiple|Market Cap to Earnings and Growth Ratio SCPH (scPharmaceuticals, Inc.)|Price/Earnings to Growth Multiple TECX|Tonix Pharmaceuticals (TNXP) - Growth-Adjusted Market Cap to Net Income|PEG Multiple SXTC|PEG Multiple Eupraxia Pharma (EPRX)|Price/Earnings to Growth Ratio BioHarvest Sciences Inc. BHST|EXOZ - Price/Earnings to Growth Multiple|ORMP: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate abvcpharma.com (ABVC)|Price/Earnings to Growth Ratio Cumberland Pharma|Price/Earnings to Growth Ratio QNTM|PEG Multiple FGEN|TELO (Telomir Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Rani Therapeutics Holdings RANI|SNYR - Price/Earnings to Growth Multiple|RLYB - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income lexariabioscience.com LEXX|PULM: PEG Multiple|Growth-Adjusted P/E Ratio PTHL|Price/Earnings to Growth Ratio Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc.) - Company Value to Earnings Growth Ratio|PEG Multiple IBO|Growth-Adjusted Market Cap to Net Income TNF Pharmaceuticals, Inc.|PEG Multiple YCBD (cbdMD, Inc.)|PRFX (PainReform Corp) - Market Cap to Earnings and Growth Ratio|CYTO: Price/Earnings to Growth Multiple|LIPO - PEG Multiple|OptiNose, Inc. (OPTN) - Price/Earnings to Growth Ratio|PIRS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Procaps|Price/Earnings to Growth Multiple Petros (PTPI)|Price/Earnings to Growth Ratio Qilian International Corp (QLI)|PEG Multiple acelyrin.com (SLRN)|PEG Multiple TFFP (TFF Pharmaceuticals)